



Colchicine poisoning: the dark side of an ancient drug

Yaron Finkelstein, Steven E. Aks, Janine R. Hutson, David N. Juurlink, Patricia Nguyen, Gal Dubnov-Raz, Uri Pollak, Gideon Koren & Yedidia Bentur

To cite this article: Yaron Finkelstein, Steven E. Aks, Janine R. Hutson, David N. Juurlink, Patricia Nguyen, Gal Dubnov-Raz, Uri Pollak, Gideon Koren & Yedidia Bentur (2010) Colchicine poisoning: the dark side of an ancient drug, *Clinical Toxicology*, 48:5, 407-414, DOI: [10.3109/15563650.2010.495348](https://doi.org/10.3109/15563650.2010.495348)

To link to this article: <https://doi.org/10.3109/15563650.2010.495348>



Published online: 29 Jun 2010.



Submit your article to this journal [↗](#)



Article views: 8223



View related articles [↗](#)



Citing articles: 90 View citing articles [↗](#)

REVIEW

Colchicine poisoning: the dark side of an ancient drug

YARON FINKELSTEIN^{1,2}, STEVEN E. AKS³, JANINE R. HUTSON¹, DAVID N. JUURLINK¹, PATRICIA NGUYEN¹, GAL DUBNOV-RAZ⁴, URI POLLAK⁵, GIDEON KOREN¹, and YEDIDIA BENTUR⁶

¹Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

²Clinical Pharmacology Unit, Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA

³Toxikon Consortium, University of Illinois, Chicago, IL, USA

⁴Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel

⁵Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel

⁶Israel Poison Information Center, Rambam Health Care Campus, The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Introduction. Colchicine is used mainly for the treatment and prevention of gout and for familial Mediterranean fever (FMF). It has a narrow therapeutic index, with no clear-cut distinction between nontoxic, toxic, and lethal doses, causing substantial confusion among clinicians. Although colchicine poisoning is sometimes intentional, unintentional toxicity is common and often associated with a poor outcome. **Methods.** We performed a systematic review by searching OVID MEDLINE between 1966 and January 2010. The search strategy included “colchicine” and “poisoning” or “overdose” or “toxicity” or “intoxication.” **Toxicokinetics.** Colchicine is readily absorbed after oral administration, but undergoes extensive first-pass metabolism. It is widely distributed and binds to intracellular elements. Colchicine is primarily metabolized by the liver, undergoes significant enterohepatic re-circulation, and is also excreted by the kidneys. **Therapeutic and toxic doses.** The usual adult oral doses for FMF is 1.2–2.4 mg/day; in acute gout 1.2 mg/day and for gout prophylaxis 0.5–0.6 mg/day three to four times a week. High fatality rate was reported after acute ingestions exceeding 0.5 mg/kg. The lowest reported lethal doses of oral colchicine are 7–26 mg. **Drug interactions.** CYP 3A4 and P-glycoprotein inhibitors, such as clarithromycin, erythromycin, ketoconazole, ciclosporin, and natural grapefruit juice can increase colchicine concentrations. Co-administration with statins may increase the risk of myopathy. **Mechanisms of toxicity.** Colchicine's toxicity is an extension of its mechanism of action – binding to tubulin and disrupting the microtubular network. As a result, affected cells experience impaired protein assembly, decreased endocytosis and exocytosis, altered cell morphology, decreased cellular motility, arrest of mitosis, and interrupted cardiac myocyte conduction and contractility. The culmination of these mechanisms leads to multi-organ dysfunction and failure. **Reproductive toxicology and lactation.** Colchicine was not shown to adversely affect reproductive potential in males or females. It crosses the placenta but there is no evidence of fetal toxicity. Colchicine is excreted into breast milk and considered compatible with lactation. **Clinical features.** Colchicine poisoning presents in three sequential and usually overlapping phases: 1) 10–24 h after ingestion – gastrointestinal phase mimicking gastroenteritis may be absent after intravenous administration; 2) 24 h to 7 days after ingestion – multi-organ dysfunction. Death results from rapidly progressive multi-organ failure and sepsis. Delayed presentation, pre-existing renal or liver impairment are associated with poor prognosis. 3) Recovery typically occurs within a few weeks of ingestion, and is generally a complete recovery barring complications of the acute illness. **Diagnosis.** History of ingestion of tablets, parenteral administration, or consumption of colchicine-containing plants suggest the diagnosis. Colchicine poisoning should be suspected in patients with access to the drug and the typical toxidrome (gastroenteritis, hypotension, lactic acidosis, and prerenal azotemia). **Management.** Timely gastrointestinal decontamination should be considered with activated charcoal, and very large, recent (<60 min) ingestions may warrant gastric lavage. Supportive treatments including administration of granulocyte colony-stimulating factor are the mainstay of treatment. Although a specific experimental treatment (Fab fragment antibodies) for colchicine poisoning has been used, it is not commercially available. **Conclusion.** Although colchicine poisoning is relatively uncommon, it is imperative to recognize its features as it is associated with a high mortality rate when missed.

Keywords Colchicine; Poisoning; Toxicity; Overdose; Colchicum autumnale

Introduction

Colchicine is a neutral lipophilic alkaloid with weak anti-inflammatory activity. It is extracted from two plants: *Colchicum autumnale* (autumn crocus, meadow saffron) and *Gloriosa superba* (glory lily). Colchicine has been used for centuries for the treatment of acute gout and has been approved by the FDA for gout prophylaxis and treatment of familial Mediterranean fever (FMF), in which it can reduce the incidence of

Received 16 April 2010; accepted 18 May 2010.

Address correspondence to Yaron Finkelstein, Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1×8, Canada and The Clinical Pharmacology Unit, Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA. E-mail: yaron.finkelstein@sickkids.ca; yaron.finkelstein@childrens.harvard.edu

the primary complication, systemic amyloidosis.¹ Colchicine may also play a role in the treatment of various other conditions such as recurrent pericarditis, scleroderma, Behcet's syndrome, and Sweet's syndrome but the data are often limited and inconclusive.^{2,3}

The use of colchicine is limited by its toxicity. It is safe when administered according to established therapeutic guidelines in FMF. However, gastrointestinal side effects can occur before the relief of acute gouty pain even when using recommended doses.^{4,5} At excessive doses, colchicine can cause serious systemic toxicity. Acute colchicine poisoning is uncommon, but is associated with a high mortality rate. It is essential, therefore, that clinicians recognize and are familiar with colchicine poisoning.

The objective of this article is to review colchicine poisoning, as early diagnosis and treatment can favorably influence the prognosis of this potentially fatal intoxication.

Methods

We performed a systematic review by searching OVID MEDLINE between 1966 and January 2010. Our search strategy included "colchicine" and "poisoning" or "overdose" or "toxicity" or "intoxication." This search identified 194 papers. This list was manually screened for papers relating to colchicine poisoning in humans, the mechanism of toxicity, or its clinical management. Seventy-six papers were identified as meeting the search criteria. Reference lists of identified papers were also manually screened for additional references (identifying an additional 32). Nonpeer-reviewed sources were also searched and four were included.

Toxicokinetics

Colchicine is rapidly absorbed from the gastrointestinal tract. Serum concentrations peak at 0.5–3.0 h after ingestion.⁶ Absorption is not significantly delayed even following an overdose.⁷ The drug undergoes extensive hepatic first-pass metabolism, which accounts for its relatively low systemic bioavailability, 25–50%.^{8–10} After absorption, colchicine is rapidly distributed to all tissues, where it binds to intracellular elements. In therapeutic doses, its protein binding is 10–50% and volume of distribution ranges between 2 and 12 L/kg^{11,12} but reaches up to 21 L/kg in overdose.⁷ Colchicine is eliminated primarily by hepatic metabolism by the CYP 3A4 isoform of cytochrome P450, which involves deacetylation and demethylation, followed by biliary excretion.^{13,14} Colchicine and its metabolites undergo significant enterohepatic re-circulation.^{11,15–17} The kidneys have an important role in the clearance of colchicine, and the drug's clearance is significantly reduced in patients with renal and hepatic insufficiency.

Patients with impaired renal or hepatic function are at higher risk for toxicity and need to be closely monitored even while receiving conventional dose regimens.^{11,12,18,19}

Additionally, drugs such as clarithromycin and ciclosporin which inhibit P-glycoprotein (P-gp), an integral membrane ATPase efflux pump encoded on the *MDR1 (ABCB1)* gene, can also potentiate colchicine toxicity. Inhibition of P-gp induces both increased gastrointestinal absorption and decreased efflux (e.g., from hepatocytes) leading to increased serum and intracellular colchicine concentrations. The high intracellular concentration results in greater tubulin inhibition and enhanced toxicity.^{20,21}

The mean elimination half-life of oral colchicine is 4.4–16 h in therapeutic doses and may reach 11–32 h in poisoned patients.^{7,12} Colchicine can be detected in leukocytes and in the urine for at least 9 days following a single intravenous (IV) dose.²² Its half-life in leukocytes is reported to be 60 h.²³ According to postmortem tissue analyses, colchicine accumulates at high concentrations in bone marrow, testicles, spleen, kidney, heart, liver and gastrointestinal tract, lung, and brain.⁷

Therapeutic and toxic doses

There are several dosing regimens for FMF and acute gout and treatment prophylaxis. Typical oral recommended doses of colchicine for FMF range between 1.2 and 2.4 mg/day, whereas the recommended dose for acute gout is 1.2 mg followed by a single dose of 0.6 mg at the first sign of flare, and for gout prophylaxis 0.5–0.6 mg/day three to four times a week.²³ In children with FMF, the dosage should be adjusted to body weight and ranges from 0.3 to 1.8 mg/day in children between 4 and 6 years and 0.9 to 1.8 mg/day in children between 6 and 12 years (older children are administered adult doses) and may be increased up to 2 mg/day if attacks are not controlled.²⁴ Tablets contain colchicine 0.6 or 1.0 mg,²³ and an IV solution (0.5 mg/mL) is also available in some countries.

IV colchicine is occasionally administered when a rapid response is desired or the oral route is precluded; however, the FDA recently withdrew marketing approval for IV preparations.²⁵ The risk of severe systemic poisoning with IV administration of the drug is significantly increased, partly because of lack of early gastrointestinal symptoms.^{26–28} If IV colchicine is given as a substitute for the oral form, it should not exceed 50% of the oral dose because of lack of first-pass effect.²⁶ Toxicity in these cases depends on the total cumulative dose given in a course, which should not exceed 2–4 mg in adults; no colchicine (by any route) should be given for 7 days thereafter.²⁷ The failure to follow these guidelines (with doses of 5.5–19 mg being administered) led to severe poisoning and death at 1–40 days after IV drug administration in 20 adults between 1983 and 2000.²⁷ The dose should be avoided or significantly reduced in patients with kidney failure.

In general, the risk of colchicine poisoning is dose-dependent. However, the drug has a low therapeutic index, and there is overlap between therapeutic and toxic doses and a high fatality rate when ingestion exceeds 0.5 mg/kg in acute cases.^{29,30} Gastrointestinal and coagulation disorders were reported in

doses less than 0.5 mg/kg, bone marrow aplasia and a 10% mortality rate in patients ingesting 0.5–0.8 mg/kg, and death in doses exceeding 0.8 mg/kg in acute ingestions.²⁹ Colchicine exhibits a great variation in the dose required to cause significant morbidity or mortality. There is no clear-cut line between nontoxic, toxic, and lethal doses of colchicine in either adults or children.

The lowest reported lethal doses of oral colchicine have ranged from 7 to 26 mg.^{31–35} Fatalities have also been reported following IV injection of 18 mg over 11 days, 10 mg over 5 days, and 8 mg over 3 days.^{28,36,37} In contrast, adult patients survived acute ingestions of up to 60 mg.³⁸ The youngest patient with a fatal colchicine overdose was reported as 12 months old.³⁹ However, each of these is a case report, and the generalizability of observations is limited.

Of interest is a 1966 report describing the survival of a patient after an alleged “ingestion of 350 mg of colchicine,”⁴⁰ which has been repeatedly quoted in the medical literature over the past 40 years.^{41–43} This report was of a young woman who ingested boiled tubers of *G. superba*, developed colchicine poisoning, and fully recovered. We believe the authors overestimated the amount of colchicine in the tubers. Survival after ingestion of colchicine 350 mg is inconceivable in view of the minimal lethal oral doses reported (7–26 mg)^{31–35} and the maximal reported tolerated dose of 60 mg.³⁸ Misquotation of this overestimation can result in reduced alertness to much lower but still life-threatening colchicine overdose.

Drug interactions

Interactions between colchicine and drugs or compounds that inhibit CYP 3A4 can potentially lead to increased serum and tissue colchicine concentrations and toxicity. The main specific inhibitors of CYP 3A4 known to interact with colchicine are clarithromycin, erythromycin, ketoconazole, and natural grapefruit juice, although multiple other inhibitors may interact with the drug.^{41,44–47} P-gp inhibitors reported to interact with colchicine include clarithromycin^{44,46,48} and ciclosporin.^{49–51} Concurrent use of P-gp or strong CYP 3A4 inhibitors with colchicine is contraindicated in patients with hepatic or renal impairment²³ and a dose reduction or interruption of colchicine therapy should be considered in patients taking those inhibitors who have no renal or hepatic impairment. Concomitant administration of colchicine and statins (i.e., fluvastatin, lovastatin, and pravastatin) resulted in myopathy.^{52–54} The mechanism for this interaction has not been fully elucidated but may involve disruption of the cytoskeleton by both the statin and colchicine.⁵²

Mechanisms of toxicity

Colchicine binds to the intracellular protein tubulin, preventing its alpha and beta forms from polymerizing to form microtubules. This disruption of the microtubular network results in

impaired protein assembly in the Golgi apparatus, decreased endocytosis and exocytosis, altered cell shape, depressed cellular motility, and arrest of mitosis. In toxic doses, colchicine arrests mitosis in metaphase because chromosome separation depends on microtubular function,^{16,55} thus inhibiting cell division. These effects occur in all cell lines of the body and explain both the therapeutic effects and the multi-organ toxicity seen with poisonings. The systems with the highest turnover rate, that is, bone marrow, gastrointestinal tract, and hair follicles, are the most vulnerable and most readily affected.^{56,57}

Disruption of the microtubular network also leads to decreased expression of adhesion molecules on neutrophil membranes and modulates cytokine production.⁵⁸ Colchicine may also have a direct toxic action on myocardial cells. This effect may be related to binding of the drug to microtubules in myocytes, which interferes with cardiac conduction and contractility.^{59–63} The inhibition of other important microtubular functions such as cytoplasmic motility and extracellular secretion of hormones and neurotransmitters may be involved in the devastating processes leading to multi-organ failure in cases of drug overdose.⁶⁴ Colchicine also inhibits the release of histamine from mast cells, inhibits the secretion of insulin from the pancreas, depresses central respiratory centers, induces hypertension by central vasomotor stimulation, and enhances the patient's response to sympathomimetic agents.⁶⁵

Recent studies have focused on the role of P-gp in colchicine poisoning because this transporter is an efflux protein.⁶⁶ The paucity of P-gp expression in neutrophils, together with the threefold greater concentration of colchicine detected in neutrophils compared to lymphocytes, may explain the mechanism of action of colchicine.⁵⁸ This also suggests that P-gp is an important factor in colchicine toxicity and can partly explain neutropenia and bone marrow suppression.

Reproductive toxicology and lactation

Sperm motility, which depends on microtubular function, may theoretically be reduced by colchicine. However, *in vitro* studies showed that the serum concentration required to impair sperm motility is 3,000 times higher than the concentration achieved with therapeutic dosing.⁶⁷ The reported frequency of oligospermia in adult patients treated with colchicine ranges widely, from 0% to 37%, depending on the series and the underlying disease.^{16,24,68,69} Recent data suggest that this effect is rare.⁷⁰ There is no convincing evidence of a negative effect of colchicine treatment on female fertility. In fact, by controlling attacks in pregnant women with FMF, colchicine may reduce peritoneal adhesions and mechanical infertility.⁷⁰

Small amounts of colchicine were found in cord blood samples, suggesting that it may cross the human placenta.⁷¹ Several case series have not demonstrated any effect on birth weight, duration of pregnancy, miscarriage rate, or congenital malformations.^{70,72–75} Furthermore, in 548 pregnant women treated chronically with colchicine for FMF, the rate of birth defects

and chromosomal abnormalities were consistent with the general population.⁷⁶ This large study suggests that the small number of case reports linking colchicine to Down syndrome may simply reflect chance alone.^{65,74,77} Most current policies recommend continuous colchicine therapy during pregnancy with amniocentesis performed in the fourth to fifth month.^{76,78}

Colchicine is present in breast milk and can bind to fatty acids and proteins.^{79–81} Concentrations in milk have a parallel time–concentration curve to that of plasma.⁸¹ The estimated daily amount of colchicine ingested by the nursing infant is less than one-tenth the therapeutic dose (per kilogram).¹⁶ This finding, together with the favorable outcome of more than 50 infants breast fed by colchicine-treated mothers, have led to many authors recommending continued breast-feeding in this scenario.¹⁶ The American Academy of Pediatrics categorizes colchicine as compatible with breast-feeding.⁸²

The potential effect of colchicine on childhood growth is also of concern, as growth requires cell division. However, one study found that growth was within the normal percentiles even in children treated with colchicine (0.5–1 mg/day) for long periods.²⁴ Further evaluation of this cohort demonstrated that their development and fertility were also normal.

Clinical features

Patients ingesting therapeutic oral doses of colchicine may suffer from abdominal pain, cramping, hyperperistalsis, diarrhea,

nausea, and vomiting.^{23,44} Gastrointestinal manifestations develop frequently and may precede pain relief in up to 91% of patients, limiting enthusiasm for the drug generally, and limiting its dose in many patients.⁵ The suggestion to administer colchicine at frequent intervals until gastrointestinal side effects develop is a matter of significant concern⁴ and has led to unintentional death in our experience.

The clinical course of acute colchicine poisoning is well described (Table 1). It may be divided into three sequential and usually overlapping phases.^{16,64} The *first (gastrointestinal) phase* reflects gastrointestinal mucosal damage and a cholera-like syndrome may develop.^{33,35,64,83–88} Gastrointestinal symptoms may be limited when toxicity follows IV administration.^{26–28} The *second (multi-organ) phase* is characterized by multi-organ dysfunction and metabolic derangements are also common.^{17,35,44,56,64,84,89,90} Death from acute colchicine poisoning is usually due to hemodynamic collapse and cardiac arrhythmias (typically 24–36 h after ingestion or could be sudden) or from infectious or hemorrhagic complications.^{17,91–96} Patients with early hemodynamic collapse have a particularly poor prognosis.⁹¹ Surviving patients will enter the *third phase*, which is characterized by recovery of bone marrow depression with rebound leukocytosis, resolution of organ failure, and can be followed by complete recovery.^{30,37,44,97} Myopathy, neuropathy, and combined myoneuropathy have all been reported after acute poisoning. Proximal limb weakness, distal sensory abnormalities, distal areflexia, and nerve conduction impairment compatible with

Table 1. Clinical stages of colchicine poisoning

Stage	Time of onset	Features
1. Gastrointestinal phase	0–24 h post-ingestion	Nausea, vomiting, diarrhea, abdominal discomfort Hypovolemia Leukocytosis
2. Multi-organ failure phase	1–7 days post-ingestion	Respiratory distress syndrome Cardiac arrhythmias, failure, arrest Encephalopathy, brain edema Convulsions Renal failure Liver failure Disseminated intravascular coagulation Bone marrow suppression Pancytopenia Hemolysis Metabolic derangements: metabolic acidosis, hypokalemia, hyponatremia, hypoalbuminemia, hypoglycemia (or hyperglycemia), hypophosphatemia Myopathy Neuropathy
3. Recovery phase	7–21 days post-ingestion	Secondary sepsis Resolution of organ system derangements Rebound leukocytosis Alopecia

axonal neuropathy are characteristics.^{42,64,90,98,99} Other complications include delirium, stupor and coma, convulsions, adrenal hemorrhage, disseminated intravascular coagulopathy, alopecia, and pancreatitis.^{29,30,41,42,90,99–101} Although rare, a toxic epidermal necrolysis-like reaction has also been reported, with histopathology showing subepidermal bullae and apoptosis of keratinocytes.³⁴

Similar to the third phase of acute poisoning described above, chronic colchicine toxicity includes neuromyopathy and myocardial failure. The neuromyopathy presents with proximal weakness and can also include respiratory insufficiency.¹⁰² An increase in serum creatine kinase activity is invariably observed. These features should reverse in 3–4 weeks after discontinuation of colchicine.¹⁰² The presence of myocardial failure offers a dismal prognosis.⁹³ Chronic toxicity is thought to be rare because development of gastrointestinal symptoms usually leads to stopping treatment.⁹³ Chronic toxicity is often associated with renal impairment or precipitated by an inter-current illness and is usually misdiagnosed as polymyositis or uremic neuropathy.^{35,98,102} The best predictor for myotoxicity from colchicine was found to be impaired renal function, with a creatinine clearance of 50 mL/min or less.¹⁰³

Diagnosis

Colchicine poisoning constitutes a toxicological emergency and requires rapid intervention. The diagnosis of colchicine poisoning is not difficult if a history of ingestion or parenteral administration is available. Colchicine can also be unintentionally consumed in meals in the form of the leaves of *C. autumnale* and the tubers of *G. superba* as they can be mistaken for wild garlic and sweet potatoes, respectively.^{30,84,85,104,105} In regions where FMF is endemic and colchicine use is common, physicians should maintain a high index of suspicion, because symptoms of colchicine may be misdiagnosed for other systemic diseases (e.g., enterocolitis). A diagnosis of colchicine poisoning should be investigated when a patient presents with the typical colchicine toxidrome (gastroenteritis, hypotension, lactic acidosis, and prerenal azotemia).⁴⁷ Differentiation of colchicine poisoning from enterocolitis, sepsis, nonsteroidal anti-inflammatory drug or iron poisoning (in the early phase), or heavy metal poisoning (in the later phase) is possible by the presence of severe bone marrow suppression in the second phase and proper infectious and relevant toxicological evaluations. Under-diagnosis may partly explain the small number of reported cases of colchicine poisoning.

Any patient with a known or suspected colchicine overdose should be admitted for observation for 24 h and managed as an inpatient.³⁰ Early gastrointestinal manifestations should be sought. If no symptoms and signs develop within the first 24 h after ingestion they are unlikely to appear later, and the patient may be discharged. In cases of IV colchicine overdose, gastrointestinal signs are lacking, and a higher index of suspicion and longer observation period (a few days) are needed. If clinical signs of poisoning develop, close mon-

itoring in an intensive care unit is required, anticipating the above-mentioned complications.

Laboratory studies

Baseline laboratory studies for a patient presenting with colchicine poisoning include complete blood count, glucose, electrolytes, renal and hepatic function tests, coagulation tests, creatine kinase, calcium, phosphorus, magnesium, arterial blood gases, chest X-ray, urinalysis, and continuous ECG monitoring.^{17,33,41,47,106,107} Troponin, fibrinogen, fibrinogen split products, and echocardiography should be considered depending upon the clinical picture.^{56,84,87,89,96,106} A pregnancy test is recommended in females. In the presence of organ dysfunction, a hematology blood smear displaying toxic vacuolation, gross dysplasia, and nuclear karyorrhexis should alert clinicians to possible colchicine poisoning.³⁵ Laboratory parameters should be serially monitored to detect possible delayed toxicity. Colchicine plasma concentrations may be measured by liquid chromatography-mass spectrometry, HPLC, and radioimmunoassay. However, they are neither readily available in the clinical setting, nor useful for the management of acute poisoning because there is no established correlation to severity of illness.^{95,106,107}

Management

The mainstays of treatment consist of prompt recognition of colchicine poisoning, with, if possible, determination of the dose ingested or administered, early gastrointestinal decontamination, and aggressive supportive care. Management may be difficult if multi-organ failure develops.

In early (i.e., 1–2 h after ingestion) presentations of large ingestions, efforts to remove any remaining colchicine from the gastrointestinal tract by gastric lavage followed by activated charcoal should be attempted.⁹⁰ Large amounts of the drug have been found in the stomach 24 h after ingestion,⁸³ thus the use of activated charcoal may be considered even in late presentation. Enhanced elimination with multi-dose activated charcoal (MDAC) should be considered because of colchicine's enterohepatic re-circulation¹⁷ and in cases of ingestion of colchicine-containing plants.⁸⁴ Although the efficacy of MDAC in managing colchicine poisoning has not been systematically studied, its use should be considered in patients with potentially serious or lethal ingestions. In case of vomiting, anti-emetics can be given to control emesis and facilitate activated charcoal administration. Paralytic ileus, which can develop as a complication of colchicine poisoning, may complicate the use of MDAC.^{84,90} Extracorporeal elimination (e.g., hemodialysis and hemoperfusion) is ineffective mainly because of the large volume of distribution of colchicine.^{99,108}

After decontamination, treatment is mainly supportive.³⁰ Sudden malignant arrhythmias and death have been reported in colchicine poisoning, and symptomatic patients or those

with confirmed ingested toxic doses should be monitored in an intensive care unit. Continuous monitoring of vital signs, ECG, and serial hematological and biochemical assessments is warranted. Treatment includes judicious administration of IV fluids, correction of electrolyte and acid–base balance, vasopressor drugs, antiarrhythmics, blood products, and mechanical ventilation.³⁰ Broad-spectrum antibiotics should also be given if a secondary infection is suspected or the patient is febrile.⁴⁷ Granulocyte colony-stimulating factor should be considered if there is leukopenia and is thought to accelerate production of neutrophils within the bone marrow and prevent development of septicemia.^{47,109}

Effective experimental treatment with colchicine-specific Fab fragment antibodies was reported in a single adult patient with severe colchicine poisoning.³⁸ Positive hemodynamic effects were quickly noted, although bone marrow suppression did not significantly improve. Ultimately, the patient survived a large (60 mg) overdose. Colchicine-specific Fab fragments consist of the light chain and variable region of the heavy chain of antibodies derived from goats immunized with a conjugate of colchicine and serum albumin.¹¹⁰ *In vitro* studies have shown that colchicine-specific antibodies restore the activity of tubulin inhibited by colchicine.¹¹¹ Their mechanism of action in the clinical setting is similar to that of digoxin-specific Fab fragment antibodies; both bind to the target drug allowing its redistribution into the extracellular space and intravascular compartment, and thus the removal of substantial amounts from peripheral tissues.^{33,111,112} The high affinity of the Fab fragment antibodies to colchicine prevents the drug from binding to other peripheral sites. Presently, this treatment is not commercially available.

Conclusions

Colchicine poisoning is relatively uncommon, but potentially severe, and has a high mortality rate. It may easily be overlooked because presenting gastrointestinal manifestations may resemble other systemic diseases. Aggressive supportive treatment, including granulocyte colony-stimulating factor when appropriate, is required to manage colchicine's toxic effects. Specific therapy with Fab fragment antibodies seems to be effective but, unfortunately, is not commercially available at present.

Declaration of interest

The author reports no declarations of interest. The authors alone are responsible for the content and writing of this paper.

References

- Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. *N Engl J Med* 1986; 314:1001–1005.

- Adler Y, Finkelstein Y, Guindo J, Rodriguez de la Serna A, Shoenfeld Y, Bayes-Genis A, Sagie A, Bayes de Luna A, Spodick DH. Colchicine treatment for recurrent pericarditis. A decade of experience. *Circulation* 1998; 97:2183–2185.
- Bhat A, Naguwa SM, Cheema GS, Gershwin ME. Colchicine revisited. *Ann N Y Acad Sci* 2009; 1173:766–773.
- Varughese GI, Varghese AI, Tahrani AA. Colchicine: time to rethink. *N Z Med J* 2007; 120:U2429.
- Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. *N Z Med J* 2007; 120:U2402.
- Wallace SL, Ertel NH. Plasma levels of colchicine after oral administration of a single dose. *Metabolism* 1973; 22:749–753.
- Rochdi M, Sabouraud A, Baud FJ, Bismuth C, Scherrmann JM. Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. *Hum Exp Toxicol* 1992; 11:510–516.
- Achtert G, Scherrmann JM, Christen MO. Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. *Eur J Drug Metab Pharmacokinet* 1989; 14:317–322.
- Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. *Eur J Clin Pharmacol* 1994; 46:351–354.
- Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. *J Clin Pharmacol* 1996; 36:874–883.
- Wallace SL, Omokoku B, Ertel NH. Colchicine plasma levels. Implications as to pharmacology and mechanism of action. *Am J Med* 1970; 48:443–448.
- Ben-Chetrit E, Scherrmann JM, Zylber-Katz E, Levy M. Colchicine disposition in patients with familial Mediterranean fever with renal impairment. *J Rheumatol* 1994; 21:710–713.
- Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. *Biochem Pharmacol* 1997; 53:111–116.
- Hunter AL, Klaassen CD. Biliary excretion of colchicine. *J Pharmacol Exp Ther* 1975; 192:605–617.
- Thomas G, Girre C, Scherrmann JM, Francheteau P, Steimer JL. Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. *Eur J Clin Pharmacol* 1989; 37:79–84.
- Ben-Chetrit E, Levy M. Colchicine: 1998 update. *Semin Arthritis Rheum* 1998; 28:48–59.
- Borron SW, Scherrmann JM, Baud FJ. Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. *Hum Exp Toxicol* 1996; 15:885–890.
- Leighton JA, Bay MK, Maldonado AL, Johnson RF, Schenker S, Speeg KV. The effect of liver dysfunction on colchicine pharmacokinetics in the rat. *Hepatology* 1990; 11:210–215.
- Rudi J, Raedsch R, Gerteis C, Schlenker T, Plachky J, Walter-Sack I, Sabouraud A, Scherrmann JM, Kommerell B. Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. *Scand J Gastroenterol* 1994; 29:346–351.
- Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. *Hepatology* 1992; 15:899–903.
- Declèves X, Niel E, Debray M, Scherrmann JM. Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions? *Toxicol Appl Pharmacol* 2006; 217:153–160.
- Ertel NH, Mittler JC, Akgun S, Wallace SL. Radioimmunoassay for colchicine in plasma and urine. *Science* 1976; 193:233–235.
- e-CPS website. Colchicine: Oral [product monograph]. <http://www.e-cps>. Accessed 12 June 2010.
- Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. *Arthritis Rheum* 1991; 34:973–977.

25. Terkeltaub RA. Colchicine update: 2008. *Semin Arthritis Rheum* 2009; 38:411–419.
26. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine – guidelines for use. *J Rheumatol* 1988; 15:495–499.
27. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. *J Emerg Med* 2002; 22:385–387.
28. Luciani I. Fatal i.v. colchicine injection in a 60-year-old woman. *J Emerg Nurs* 1989; 15:80–82.
29. Bismuth C, Gaultier M, Conso F. Medullary aplasia after acute colchicine poisoning. 20 cases. *Nouv Presse Med* 1977; 6:1625–1629.
30. Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. *Semin Arthritis Rheum* 1991; 21:143–155.
31. Macleod JG, Phillips L. Hypersensitivity to colchicine. *Ann Rheum Dis* 1947; 6:224–229.
32. Jarvie D, Park J, Stewart MJ. Estimation of colchicine in a poisoned patient by using high performance liquid chromatography. *Clin Toxicol* 1979; 14:375–381.
33. Maxwell MJ, Muthu P, Pritty PE. Accidental colchicine overdose. A case report and literature review. *Emerg Med J* 2002; 19:265–267.
34. Arroyo MP, Sanders S, Yee H, Schwartz D, Kamino H, Strober BE. Toxic epidermal necrolysis-like reaction secondary to colchicine overdose. *Br J Dermatol* 2004; 150:581–588.
35. Dickinson M, Juneja S. Haematological toxicity of colchicine. *Br J Haematol* 2009; 146:465.
36. Stemmermann GN, Hayashi T. Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases. *Hum Pathol* 1971; 2:321–332.
37. Liu YK, Hymowitz R, Carroll MG. Marrow aplasia induced by colchicine. A case report. *Arthritis Rheum* 1978; 21:731–735.
38. Baud FJ, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C, Rouzioux JM, Scherrmann JM. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. *N Engl J Med* 1995; 332:642–645.
39. Atas B, Caksen H, Tuncer O, Kirimi E, Akgun C, Odabas D. Four children with colchicine poisoning. *Hum Exp Toxicol* 2004; 23:353–356.
40. Gooneratne BW. Massive generalized alopecia after poisoning by *Gloriosa superba*. *Br Med J* 1966; 1:1023–1024.
41. Goldbart A, Press J, Sofer S, Kapelushnik J. Near fatal acute colchicine intoxication in a child. A case report. *Eur J Pediatr* 2000; 159:895–897.
42. Guven AG, Bahat E, Akman S, Artan R, Erol M. Late diagnosis of severe colchicine intoxication. *Pediatrics* 2002; 109:971–973.
43. Hill RN, Spragg RG, Wedel MK, Moser KM. Letter: adult respiratory distress syndrome associated with colchicine intoxication. *Ann Intern Med* 1975; 83:523–524.
44. Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E. Acute colchicine intoxication – possible role of erythromycin administration. *J Rheumatol* 1992; 19:494–496.
45. Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C. Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration. *Clin Nephrol* 2001; 55:181–182.
46. Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, Woo PC, Lau SK, Cheung BM, Yuen KY. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. *Clin Infect Dis* 2005; 41:291–300.
47. Donovan JW. Colchicine. In: Shannon MW, Borron SW, Burns MJ, eds. *Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose*. Philadelphia: Saunders/Elsevier; 2007.
48. Rollet F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P. Acute colchicine intoxication during clarithromycin administration. *Ann Pharmacother* 2004; 38:2074–2077.
49. Minetti EE, Minetti L. Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine. *J Nephrol* 2003; 16:421–425.
50. Yussim A, Bar-Nathan N, Lustig S, Shaharabani E, Geier E, Shmueli D, Nakache R, Shapira Z. Gastrointestinal, hepatorenal, and neuromuscular toxicity caused by cyclosporine–colchicine interaction in renal transplantation. *Transplant Proc* 1994; 26:2825–2826.
51. Gruberg L, Har-Zahav Y, Agranat O, Freimark D. Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter. *Transplant Proc* 1999; 31:2157–2158.
52. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. *Ann Pharmacother* 2005; 39:1368–1369.
53. Torgovnick J, Sethi N, Arsura E. Colchicine and HMG Co-A reductase inhibitors induced myopathy – a case report. *Neurotoxicology* 2006; 27:1126–1127.
54. Alayli G, Cengiz K, Canturk F, Durmus D, Akyol Y, Menekse EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. *Ann Pharmacother* 2005; 39:1358–1361.
55. Murray LM. Colchicine. In: Ford MD, Delaney KA, Ling LJ, Erickson T, eds. *Clinical Toxicology*. Philadelphia: WB Saunders Company; 2001.
56. Folpini A, Furfuri P. Colchicine toxicity – clinical features and treatment. Massive overdose case report. *J Toxicol Clin Toxicol* 1995; 33:71–77.
57. Hood RL. Colchicine poisoning. *J Emerg Med* 1994; 12:171–177.
58. Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? *Med Hypotheses* 1998; 51:377–380.
59. Klein I. Colchicine stimulates the rate of contraction of heart cells in culture. *Cardiovasc Res* 1983; 17:459–465.
60. Nath K, Shay JW, Bollon AP. Relationship between dibutyryl cyclic AMP and microtubule organization in contracting heart muscle cells. *Proc Natl Acad Sci USA* 1978; 75:319–323.
61. Limas CJ. Myocardial colchicine-binding proteins: possible relation to DNA synthesis initiation. *J Mol Cell Cardiol* 1979; 11:1137–1150.
62. Crie JS, Ord JM, Wakeland JR, Wildenthal K. Inhibition of cardiac proteolysis by colchicine. Selective effects on degradation of protein subclasses. *Biochem J* 1983; 210:63–71.
63. Mery P, Riou B, Chemla D, Lecarpentier Y. Cardiotoxicity of colchicine in the rat. *Intensive Care Med* 1994; 20:119–123.
64. Stapczynski JS, Rothstein RJ, Gaye WA, Niemann JT. Colchicine overdose: report of two cases and review of the literature. *Ann Emerg Med* 1981; 10:364–369.
65. Wallace SL. Colchicine. *Semin Arthritis Rheum* 1974; 3:369–381.
66. Nordenberg J, Kornfeld J, Wasserman L, Shafran M, Halabe E, Beery E, Landau O, Novogrodsky A, Sidi Y. Novobiocin modulates colchicine sensitivity in parental and multidrug-resistant B16 melanoma cells. *J Cancer Res Clin Oncol* 1994; 120:599–604.
67. Ben-Chetrit A, Ben-Chetrit E, Nitzan R, Ron M. Colchicine inhibits spermatozoal motility in vitro. *Int J Fertil Menopausal Stud* 1993; 38:301–304.
68. Bremner WJ, Paulsen CA. Colchicine and testicular function in man. *N Engl J Med* 1976; 294:1384–1385.
69. Sarica K, Suzer O, Gurler A, Baltaci S, Ozdiler E, Dincel C. Urological evaluation of Behcet patients and the effect of colchicine on fertility. *Eur Urol* 1995; 27:39–42.
70. Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. *Ann Rheum Dis* 2003; 62:916–919.
71. Amoura Z, Scherrmann JM, Wechsler B, Zerach X, Goodeau P. Transplacental passage of colchicine in familial Mediterranean fever. *J Rheumatol* 1994; 21:383.
72. Cousin C, Palaric JC, Jacquemard F, Lucas J, Giraud JR. Periodic disease and pregnancy. *J Gynecol Obstet Biol Reprod (Paris)* 1991; 20:554–561.

73. Ehrenfeld M, Brzezinski A, Levy M, Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. *Br J Obstet Gynaecol* 1987; 94:1186–1191.
74. Rabinovitch O, Zemer D, Kukia E, Sohar E, Mashiah S. Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever. *Am J Reprod Immunol* 1992; 28:245–246.
75. Dudin A, Rambaud-Cousson A, Shehatto M, Thalji A. Colchicine in the first trimester of pregnancy and vertebral malformations. *Arch Fr Pediatr* 1989; 46:627–628.
76. Berkenstadt M, Weisz B, Cuckle H, Di-Castro M, Guetta E, Barkai G. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. *Am J Obstet Gynecol* 2005; 193:1513–1516.
77. Pras M, Gafni J, Jacob ET, Cabili S, Zemer D, Sohar E. Recent advances in familial Mediterranean fever. *Adv Nephrol Necker Hosp* 1984; 13:261–270.
78. Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, Pras M. The changing face of familial Mediterranean fever. *Semin Arthritis Rheum* 1996; 26:612–627.
79. Milunsky JM. Breast-feeding during colchicine therapy for familial Mediterranean fever. *J Pediatr* 1991; 119:164.
80. Guillonnet M, Aigrain EJ, Galliot M, Binet MH, Darbois Y. Colchicine is excreted at high concentrations in human breast milk. *Eur J Obstet Gynecol Reprod Biol* 1995; 61(2):177–178.
81. Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. *Arthritis Rheum* 1996; 39:1213–1217.
82. Drugs AAoPCo. Transfer of drugs and other chemicals into human milk. *Pediatrics* 2001; 108:776–789.
83. Ellwood MG, Robb GH. Self-poisoning with colchicine. *Postgrad Med J* 1971; 47:129–131.
84. Brvar M, Ploj T, Kozelj G, Mozina M, Noc M, Bunc M. Case report: fatal poisoning with *Colchicum autumnale*. *Crit Care* 2004; 8:R56–R59.
85. Gabrsek L, Lesnicar G, Krivec B, Voga G, Sibanc B, Blatnik J, Jagodic B. Accidental poisoning with autumn crocus. *J Toxicol Clin Toxicol* 2004; 42:85–88.
86. Blackham RE, Little M, Baker S, Augustson BM, MacQuillan GC. Unsuspected colchicine overdose in a female patient presenting as an acute abdomen. *Anaesth Intensive Care* 2007; 35:437–439.
87. Mendis S. Colchicine cardiotoxicity following ingestion of *Gloriosa superba* tubers. *Postgrad Med J* 1989; 65:752–755.
88. Valenzuela P, Paris E, Oberpauer B, Rios JC, Concha F. Overdose of colchicine in a three-year-old child. *Vet Hum Toxicol* 1995; 37:366–367.
89. Mullins ME, Robertson DG, Norton RL. Troponin I as a marker of cardiac toxicity in acute colchicine overdose. *Am J Emerg Med* 2000; 18:743–744.
90. Murray SS, Kramlinger KG, McMichan JC, Mohr DN. Acute toxicity after excessive ingestion of colchicine. *Mayo Clin Proc* 1983; 58:528–532.
91. Sauder P, Kopferschmitt J, Jaeger A, Mantz JM. Haemodynamic studies in eight cases of acute colchicine poisoning. *Hum Toxicol* 1983; 2:169–173.
92. Neuss MN, McCallum RM, Brenckman WD, Silberman HR. Long-term colchicine administration leading to colchicine toxicity and death. *Arthritis Rheum* 1986; 29:448–449.
93. Montseny JJ, Meyrier A, Gherardi RK. Colchicine toxicity in patients with chronic renal failure. *Nephrol Dial Transplant* 1996; 11:2055–2058.
94. Milne ST, Meek PD. Fatal colchicine overdose: report of a case and review of the literature. *Am J Emerg Med* 1998; 16:603–608.
95. Deveaux M, Hubert N, Demarly C. Colchicine poisoning: case report of two suicides. *Forensic Sci Int* 2004; 143:219–222.
96. Miller MA, Hung YM, Haller C, Galbo M, Levsky ME. Colchicine-related death presenting as an unknown case of multiple organ failure. *J Emerg Med* 2005; 28:445–448.
97. Boruchow IB. Bone marrow depression associated with acute colchicine toxicity in the presence of hepatic dysfunction. *Cancer* 1966; 19:541–543.
98. Altiparmak MR, Pamuk ON, Pamuk GE, Hamuryudan V, Ataman R, Serdengecti K. Colchicine neuromyopathy: a report of six cases. *Clin Exp Rheumatol* 2002; 20:S13–S16.
99. Heaney D, Derghazarian CB, Pineo GF, Ali MA. Massive colchicine overdose: a report on the toxicity. *Am J Med Sci* 1976; 271:233–238.
100. Naidus RM, Rodvien R, Mielke CHJ. Colchicine toxicity: a multisystem disease. *Arch Intern Med* 1977; 137:394–396.
101. Baldwin LR, Talbert RL, Samples R. Accidental overdose of insufflated colchicine. *Drug Saf* 1990; 5:305–312.
102. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. *N Engl J Med* 1987; 316:1562–1568.
103. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. *J Rheumatol* 1991; 18:264–269.
104. Klintschar M, Beham-Schmidt C, Radner H, Henning G, Roll P. Colchicine poisoning by accidental ingestion of meadow saffron (*Colchicum autumnale*): pathological and medicolegal aspects. *Forensic Sci Int* 1999; 106:191–200.
105. Sundov Z, Nincevic Z, Definis-Gojanovic M, Glavina-Durdov M, Jukic I, Hulina N, Tonkic A. Fatal colchicine poisoning by accidental ingestion of meadow saffron-case report. *Forensic Sci Int* 2005; 149:253–256.
106. van Heyningen C, Watson ID. Troponin for prediction of cardiovascular collapse in acute colchicine overdose. *Emerg Med J* 2005; 22:599–600.
107. Brncic N, Viskovic I, Peric R, Dirlic A, Vitezic D, Cuculic D. Accidental plant poisoning with *Colchicum autumnale*: report of two cases. *Croat Med J* 2001; 42:673–675.
108. Bismuth C, Fournier PE, Galliot M. Biological evaluation of hemoperfusion in acute poisoning. *Clin Toxicol* 1981; 18:1213–1223.
109. Harris R, Marx G, Gillett M, Kark A, Arunanthy S. Colchicine-induced bone marrow suppression: treatment with granulocyte colony-stimulating factor. *J Emerg Med* 2000; 18:435–440.
110. Sabouraud A, Urtizberea M, Grandgeorge M, Gattel P, Makula ME, Scherrmann JM. Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments. *Toxicology* 1991; 68:121–132.
111. Rouan SK, Otterness IG, Cunningham AC, Holden HE, Rhodes CT. Reversal of colchicine-induced mitotic arrest in Chinese hamster cells with a colchicine-specific monoclonal antibody. *Am J Pathol* 1990; 137:779–787.
112. Wolff J, Capraro HG, Brossi A, Cook GH. Colchicine binding to antibodies. *J Biol Chem* 1980; 255:7144–7148.
113. Finkelstein Y. Colchicine. In: Erickson TB, Ahrens WR, Aks SE, Baum CR, Ling LJ, eds. *Pediatric Toxicology: Diagnosis and Management of the Poisoned Child*. Toronto: McGraw-Hill; 2005:253–257.